drugset
drugset / Trial / NCT05005338

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

NCT05005338 ↗

Phase 1 Completed 8 enrolled Biogen Denali Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single center, non-randomized, open label Phase 1 study to determine the PK and absolute bioavailability of BIIB122 (DNL151) in 2 conditions: following a single, oral dose of BIIB122 (DNL151) and following consecutive days of oral dosing, approximating steady state.

Timeline

Start
2021-07-28
Primary completion
2021-09-23
Completion
2021-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB122 Small molecule — Oral

Indications

No indication recorded.